Endogenous estrogen regulates somatostatin-induced rebound GH secretion in postmenopausal women

Johannes D Veldhuis, Dana Erickson, Rebecca Yang, Paul Y Takahashi, Cyril Bowers

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Systemic concentrations of T, estradiol (E2), GH, IGF-1, and IGF binding protein-3 decline in healthy aging individuals. Conversely, T and E2 stimulate GH and IGF-1 production in hypogonadal patients. Hypothesis: Because E2 stimulates GH secretion, putatively via the nuclear estrogen receptor-α and E2 and GH fall with menopause, we postulated that diminished endogenous E2 contributes to low GH output in older women. Location: The study was conducted at the Mayo Center for Clinical and Translational Science. Study Design: This was a randomized, double-blind, controlled study in 60 healthy postmenopausal women treated with the following: 1) double placebo; 2) anastrozole, a potent inhibitor of aromatase-enzyme activity, which mediates E2 synthesis from T; and/or 3) fulvestrant, a selective estrogen receptor-α antagonist. Methods: GH pulse generation was quantified by frequent GH sampling before and after shortterm iv somatostatin infusion, thought to induce hypothalamic GHRH-mediated rebound-like GH secretion. Results: On anastrozole, E2 fell from 3.1±0.35 pg/mL to 0.36±0.04 pg/mL, and estrone from 13± 1.4 pg/mL to 1.9 ± 0.01 pg/mL (P < .001) by mass spectrometry. Estrogen values were unchanged by fulvestrant. T concentrations did not change. One-hour peak GH rebound after somatostatin infusion declined markedly during both estrogen-deprivation schedules P< .001).Mean(150 min) maximal GH rebound decreased comparably (P < .001). Measures of GH rebound correlated negatively with computed tomography-estimated abdominal visceral fat (all P < .05). Conclusion: These data suggest a previously unrecognized dependence of hypothalamo-pituitary GH regulation on low levels of endogenous estrogen after menopause.

Original languageEnglish (US)
Pages (from-to)4298-4304
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume101
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Somatostatin
Estrogens
Menopause
Insulin-Like Growth Factor I
Aromatase Inhibitors
Insulin-Like Growth Factor Binding Protein 3
Intra-Abdominal Fat
Estrone
Enzyme activity
Enzyme Inhibitors
Double-Blind Method
Estrogen Receptors
Tomography
Mass spectrometry
Estradiol
Mass Spectrometry
Appointments and Schedules
Aging of materials
Fats
Placebos

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Endogenous estrogen regulates somatostatin-induced rebound GH secretion in postmenopausal women. / Veldhuis, Johannes D; Erickson, Dana; Yang, Rebecca; Takahashi, Paul Y; Bowers, Cyril.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 101, No. 11, 01.11.2016, p. 4298-4304.

Research output: Contribution to journalArticle

Veldhuis, Johannes D ; Erickson, Dana ; Yang, Rebecca ; Takahashi, Paul Y ; Bowers, Cyril. / Endogenous estrogen regulates somatostatin-induced rebound GH secretion in postmenopausal women. In: Journal of Clinical Endocrinology and Metabolism. 2016 ; Vol. 101, No. 11. pp. 4298-4304.
@article{cde20ca10c2f4187b9c0d2d0f5fb7c05,
title = "Endogenous estrogen regulates somatostatin-induced rebound GH secretion in postmenopausal women",
abstract = "Background: Systemic concentrations of T, estradiol (E2), GH, IGF-1, and IGF binding protein-3 decline in healthy aging individuals. Conversely, T and E2 stimulate GH and IGF-1 production in hypogonadal patients. Hypothesis: Because E2 stimulates GH secretion, putatively via the nuclear estrogen receptor-α and E2 and GH fall with menopause, we postulated that diminished endogenous E2 contributes to low GH output in older women. Location: The study was conducted at the Mayo Center for Clinical and Translational Science. Study Design: This was a randomized, double-blind, controlled study in 60 healthy postmenopausal women treated with the following: 1) double placebo; 2) anastrozole, a potent inhibitor of aromatase-enzyme activity, which mediates E2 synthesis from T; and/or 3) fulvestrant, a selective estrogen receptor-α antagonist. Methods: GH pulse generation was quantified by frequent GH sampling before and after shortterm iv somatostatin infusion, thought to induce hypothalamic GHRH-mediated rebound-like GH secretion. Results: On anastrozole, E2 fell from 3.1±0.35 pg/mL to 0.36±0.04 pg/mL, and estrone from 13± 1.4 pg/mL to 1.9 ± 0.01 pg/mL (P < .001) by mass spectrometry. Estrogen values were unchanged by fulvestrant. T concentrations did not change. One-hour peak GH rebound after somatostatin infusion declined markedly during both estrogen-deprivation schedules P< .001).Mean(150 min) maximal GH rebound decreased comparably (P < .001). Measures of GH rebound correlated negatively with computed tomography-estimated abdominal visceral fat (all P < .05). Conclusion: These data suggest a previously unrecognized dependence of hypothalamo-pituitary GH regulation on low levels of endogenous estrogen after menopause.",
author = "Veldhuis, {Johannes D} and Dana Erickson and Rebecca Yang and Takahashi, {Paul Y} and Cyril Bowers",
year = "2016",
month = "11",
day = "1",
doi = "10.1210/jc.2016-2080",
language = "English (US)",
volume = "101",
pages = "4298--4304",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Endogenous estrogen regulates somatostatin-induced rebound GH secretion in postmenopausal women

AU - Veldhuis, Johannes D

AU - Erickson, Dana

AU - Yang, Rebecca

AU - Takahashi, Paul Y

AU - Bowers, Cyril

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Systemic concentrations of T, estradiol (E2), GH, IGF-1, and IGF binding protein-3 decline in healthy aging individuals. Conversely, T and E2 stimulate GH and IGF-1 production in hypogonadal patients. Hypothesis: Because E2 stimulates GH secretion, putatively via the nuclear estrogen receptor-α and E2 and GH fall with menopause, we postulated that diminished endogenous E2 contributes to low GH output in older women. Location: The study was conducted at the Mayo Center for Clinical and Translational Science. Study Design: This was a randomized, double-blind, controlled study in 60 healthy postmenopausal women treated with the following: 1) double placebo; 2) anastrozole, a potent inhibitor of aromatase-enzyme activity, which mediates E2 synthesis from T; and/or 3) fulvestrant, a selective estrogen receptor-α antagonist. Methods: GH pulse generation was quantified by frequent GH sampling before and after shortterm iv somatostatin infusion, thought to induce hypothalamic GHRH-mediated rebound-like GH secretion. Results: On anastrozole, E2 fell from 3.1±0.35 pg/mL to 0.36±0.04 pg/mL, and estrone from 13± 1.4 pg/mL to 1.9 ± 0.01 pg/mL (P < .001) by mass spectrometry. Estrogen values were unchanged by fulvestrant. T concentrations did not change. One-hour peak GH rebound after somatostatin infusion declined markedly during both estrogen-deprivation schedules P< .001).Mean(150 min) maximal GH rebound decreased comparably (P < .001). Measures of GH rebound correlated negatively with computed tomography-estimated abdominal visceral fat (all P < .05). Conclusion: These data suggest a previously unrecognized dependence of hypothalamo-pituitary GH regulation on low levels of endogenous estrogen after menopause.

AB - Background: Systemic concentrations of T, estradiol (E2), GH, IGF-1, and IGF binding protein-3 decline in healthy aging individuals. Conversely, T and E2 stimulate GH and IGF-1 production in hypogonadal patients. Hypothesis: Because E2 stimulates GH secretion, putatively via the nuclear estrogen receptor-α and E2 and GH fall with menopause, we postulated that diminished endogenous E2 contributes to low GH output in older women. Location: The study was conducted at the Mayo Center for Clinical and Translational Science. Study Design: This was a randomized, double-blind, controlled study in 60 healthy postmenopausal women treated with the following: 1) double placebo; 2) anastrozole, a potent inhibitor of aromatase-enzyme activity, which mediates E2 synthesis from T; and/or 3) fulvestrant, a selective estrogen receptor-α antagonist. Methods: GH pulse generation was quantified by frequent GH sampling before and after shortterm iv somatostatin infusion, thought to induce hypothalamic GHRH-mediated rebound-like GH secretion. Results: On anastrozole, E2 fell from 3.1±0.35 pg/mL to 0.36±0.04 pg/mL, and estrone from 13± 1.4 pg/mL to 1.9 ± 0.01 pg/mL (P < .001) by mass spectrometry. Estrogen values were unchanged by fulvestrant. T concentrations did not change. One-hour peak GH rebound after somatostatin infusion declined markedly during both estrogen-deprivation schedules P< .001).Mean(150 min) maximal GH rebound decreased comparably (P < .001). Measures of GH rebound correlated negatively with computed tomography-estimated abdominal visceral fat (all P < .05). Conclusion: These data suggest a previously unrecognized dependence of hypothalamo-pituitary GH regulation on low levels of endogenous estrogen after menopause.

UR - http://www.scopus.com/inward/record.url?scp=84994860422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994860422&partnerID=8YFLogxK

U2 - 10.1210/jc.2016-2080

DO - 10.1210/jc.2016-2080

M3 - Article

C2 - 27459535

AN - SCOPUS:84994860422

VL - 101

SP - 4298

EP - 4304

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -